Overview
Brain dopamine-serotonin vesicular transport disease (also known as DTDS or SLC18A2-related disorder) is an extremely rare genetic condition that affects how the brain packages and releases two important chemical messengers: dopamine and serotonin. These chemicals play key roles in controlling movement, mood, sleep, and many other body functions. The disease is caused by mutations in the SLC18A2 gene, which provides instructions for making a protein called VMAT2 (vesicular monoamine transporter 2). This protein is responsible for loading dopamine and serotonin into tiny storage packets (vesicles) inside nerve cells so they can be properly released and used. Symptoms typically begin in infancy and include movement problems such as involuntary muscle contractions (dystonia), difficulty controlling voluntary movements, tremor, and delays in reaching motor milestones like sitting, crawling, and walking. Children may also experience mood disturbances, sleep problems, excessive sweating, and episodes that can look like a movement crisis. Some children have intellectual disability, though cognitive abilities can vary. Treatment is currently limited and mainly supportive. Some patients may partially respond to medications that affect dopamine or serotonin pathways, but there is no cure at this time. Management involves a team of specialists working together to address movement difficulties, developmental delays, and other symptoms. Early diagnosis through genetic testing is important so that supportive therapies can be started as soon as possible.
Key symptoms:
Involuntary muscle contractions and abnormal postures (dystonia)Tremor or shakingDifficulty with voluntary movementsDelayed motor milestones such as sitting, crawling, and walkingLow muscle tone in infancyExcessive sweatingSleep disturbancesMood changes or irritabilityEye movement abnormalitiesDifficulty with speech developmentIntellectual disability (variable severity)Episodes of worsening movement problems (movement crises)Feeding difficulties in infancyDroolingReduced facial expression
Clinical phenotype terms (31)— hover any for plain English
Autosomal recessive
Passed on when both parents carry the same gene change; often skips generations
Infantile
Begins in infancy, roughly 1 month to 2 years old
Treatments
No FDA-approved treatments are currently listed for Brain dopamine-serotonin vesicular transport disease.
View clinical trials →Clinical Trials
View all trials with filters →No actively recruiting trials found for Brain dopamine-serotonin vesicular transport disease at this time.
New trials open frequently. Follow this disease to get notified.
Specialists
View all specialists →No specialists are currently listed for Brain dopamine-serotonin vesicular transport disease.
Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Travel Grants
No travel grants are currently matched to Brain dopamine-serotonin vesicular transport disease.
Community
No community posts yet. Be the first to share your experience with Brain dopamine-serotonin vesicular transport disease.
Start the conversation →Latest news about Brain dopamine-serotonin vesicular transport disease
No recent news articles for Brain dopamine-serotonin vesicular transport disease.
Follow this condition to be notified when news becomes available.
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Questions for your doctor
Bring these to your next appointment
- Q1.What specific mutation was found in my child's SLC18A2 gene, and what does it mean for the expected severity of the disease?,Are there any medications that might help improve my child's movement symptoms, and what are the potential side effects?,What therapies (physical, occupational, speech) should we start, and how often should they occur?,What should I do if my child has a severe movement crisis at home — when should I go to the emergency room?,Are there any clinical trials or research studies that my child might be eligible for?,How should we handle feeding difficulties, and should we consider a feeding tube?,Can you connect us with other families affected by this condition or with a specialized neurotransmitter disorder center?
Common questions about Brain dopamine-serotonin vesicular transport disease
What is Brain dopamine-serotonin vesicular transport disease?
Brain dopamine-serotonin vesicular transport disease (also known as DTDS or SLC18A2-related disorder) is an extremely rare genetic condition that affects how the brain packages and releases two important chemical messengers: dopamine and serotonin. These chemicals play key roles in controlling movement, mood, sleep, and many other body functions. The disease is caused by mutations in the SLC18A2 gene, which provides instructions for making a protein called VMAT2 (vesicular monoamine transporter 2). This protein is responsible for loading dopamine and serotonin into tiny storage packets (vesicl
How is Brain dopamine-serotonin vesicular transport disease inherited?
Brain dopamine-serotonin vesicular transport disease follows a autosomal recessive inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.
At what age does Brain dopamine-serotonin vesicular transport disease typically begin?
Typical onset of Brain dopamine-serotonin vesicular transport disease is infantile. Age of onset can vary across affected individuals.